Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta

Next Previous
X
Search
Trial Profile

Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Damoctocog alfa pegol (Primary) ; Efmoroctocog alfa
  • Indications Haemophilia A
  • Focus Pharmacokinetics
  • Sponsors Bayer

    • Most Recent Events

    • 08 Dec 2020 Results of dose-normalized analyses presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 01 Sep 2019 Results assessing pharmacokinetic profiles of BAY94-9027 and rFVIIIFc published in the Annals of Hematology
    • 13 Aug 2019 Primary endpoint (AUC from time 0 to the last data point (AUC0-tlast): non-inferiority of Jivi (BAY94-9027) with Eloctate (rFVIIIFc)) has been met, according to a Bayer media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top